Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Mural Oncology (Nasdaq: MURA), a clinical-stage immuno-oncology company focused on developing engineered therapies targeting cytokine pathways, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mural Oncology (Nasdaq: MURA), a clinical-stage immuno-oncology company focused on developing engineered therapies targeting cytokine pathways, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. CEO Caroline Loew, Ph.D., will deliver a presentation on March 4, 2025, at 3:10 p.m. ET.
The presentation will be accessible via live webcast through the company's investor relations website at ir.muraloncology.com/events-and-presentations. For those unable to attend the live session, a recorded version will be made available for later viewing on the same platform.
Details
News Market Reaction – MURA
The recorded move for MURA in the trading session of this news was +0.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways, today announced that CEO Caroline Loew, Ph.D., will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025 and 3:10 p.m. ET. A live webcast of the presentation will be available at https://ir.muraloncology.com/events-and-presentations. A replay of the webcast will be archived and available following the event.
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. Our lead candidate, nemvaleukin alfa, is currently in potentially registrational trials in platinum-resistant ovarian cancer and mucosal melanoma reading out in late Q1/early Q2 and Q2 of 2025, respectively. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology’s website at www.muraloncology.com and follow us on LinkedIn and X.
Contact:
Katie Sullivan
katie.sullivan@muraloncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.